Smith & Nephew plc Stock Deutsche Boerse AG

Equities

NPWA

US83175M2052

Medical Equipment, Supplies & Distribution

Delayed Deutsche Boerse AG 02:01:09 2024-05-15 am EDT 5-day change 1st Jan Change
23.8 EUR +2.59% Intraday chart for Smith & Nephew plc +2.59% -3.25%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 5.82B 5.36B Sales 2025 * 6.12B 5.64B Capitalization 11.17B 10.29B
Net income 2024 * 541M 498M Net income 2025 * 694M 639M EV / Sales 2024 * 2.36 x
Net Debt 2024 * 2.56B 2.35B Net Debt 2025 * 2.23B 2.05B EV / Sales 2025 * 2.19 x
P/E ratio 2024 *
21.7 x
P/E ratio 2025 *
16.6 x
Employees 18,452
Yield 2024 *
2.98%
Yield 2025 *
3.35%
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.59%
1 week+2.59%
Current month+4.39%
1 month+7.21%
3 months-7.75%
6 months+0.85%
Current year-3.25%
More quotes
1 week
23.20
Extreme 23.2
23.80
1 month
22.20
Extreme 22.2
23.80
Current year
22.20
Extreme 22.2
26.60
1 year
20.20
Extreme 20.2
29.80
3 years
20.20
Extreme 20.2
37.40
5 years
20.20
Extreme 20.2
47.60
10 years
20.20
Extreme 20.2
47.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-03-31
Director of Finance/CFO 56 Nov. 30
Compliance Officer - 99-03-31
Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Director/Board Member 62 23-09-13
Chairman 63 23-04-25
More insiders
Date Price Change
24-05-15 23.8 +2.59%
24-05-14 23.2 -0.85%
24-05-13 23.4 +0.86%
24-05-10 23.2 0.00%
24-05-09 23.2 0.00%

Delayed Quote Deutsche Boerse AG, May 15, 2024 at 02:01 am EDT

More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows: - orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders); - sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.; - wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc. The United States accounts for 53.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.81 USD
Average target price
16.35 USD
Spread / Average Target
+27.61%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW